A week with one hard headline and one hopeful one. The hard one needs your attention now, while you can still act on it.

More employers are drawing a line on GLP-1 coverage for 2027, and it lands right in open enrollment season.

Walmart, the country's largest private employer, said it will cover Ozempic and Mounjaro at no cost for eligible employees with type 2 diabetes starting in 2027, subject to prior authorization. But that same benefit will not cover those medications when they are prescribed solely for weight loss. It is part of a wider split: SHRM's 2026 survey found 47% of responding employers covered GLP-1s for type 2 diabetes, compared with only 15% for weight management. And a Business Group on Health survey of 127 employers found obesity coverage fell from 72% in 2025 to 60% in 2026, with 14% saying they have already dropped or plan to drop weight-management coverage by 2027. Starbucks has already ended coverage for weight-loss prescriptions for benefits-eligible employees.

What this means for you: Do not assume next year's plan looks like this year's plan. If you get coverage through work, check your 2027 drug list now, during open enrollment, and look for your medication by name. A coverage change is a paperwork problem to solve early, not a reason to panic and not a reason to change anything about your daily habits on your own. Your strength work, your protein, your sleep, and your routines still matter whatever the plan says.

→ Raise with your prescriber: "If my plan stops covering my medication for weight management in 2027, what should we plan now so there is no gap in January?"

Source: SHRM, October 2026:

⚡ Quick hit: A next-generation drug just beat Ozempic head to head, with caveats worth hearing. In a Phase 3 trial in adults with type 2 diabetes, Eli Lilly's experimental retatrutide, a once-weekly drug that targets three gut receptors instead of one, lowered A1C by an average of 2.2 percentage points versus 1.8 for the highest approved Ozempic dose, and patients lost about 19.5% to 20.9% of body weight over 80 weeks versus 9.4% on Ozempic. The trade-off was real too: stomach side effects were more common and more people stopped treatment than on Ozempic. This is preliminary data, not an approved drug, and detailed results are still to come, so think of it as a promising next chapter, not a reason to rethink your current plan.

Source: MedCity News, October 2026:

That's this week, translated. Check your plan, keep your routines, and I'll be here when the headlines are harder to love, too. 💛

Suzette

Reply

Avatar

or to participate